Study of new special immunosuppressive strategy for ABO incompatible transplantation

点击翻译按钮获取中文摘要

In Japan, the shortage of grafts has encouraged us to perform living donor liver transplantation (LDLT) across the ABO blood barrier. To decide the treatment for an ABO-I recipient, the amount of anti-A/B antibody (Ab) is very important. At present, the quantity of anti-A/B Ab is represented by the agglutination titer. We developed an enzyme linked immunosorbent assay (ELISA) to measure anti-A/B Ab, and assessed its usefulness in clinical practice in this study.In the assessment of all sera, the correlation between the O.D. and the titer of anti-A/B Ab were moderate. However, in the assessment of each recipient, the correlation between the O.D. and the titer of anti-A/B Ab was strong or moderate. Moreover, this investigation suggested that with our method it was possible to detect Ab-mediated rejection much earlier.In conclusion, our ELISA method is useful to detect changes in individually anti-A/B Ab and may have the possibility of using ELISA in clinical cases.